Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Enhance immune response to DNA vaccine based on a novel multicomponent supramolecular assembly

Xianfeng Zhou\textsuperscript{a,b}, Bin Liu\textsuperscript{b}, Xianghui Yu\textsuperscript{a,b}, Xiao Zha\textsuperscript{b,c}, Xizhen Zhang\textsuperscript{a}, Xueyun Wang\textsuperscript{a}, Yu Chen\textsuperscript{a}, Yan Chen\textsuperscript{a}, Yue Chen\textsuperscript{a}, Yaming Shan\textsuperscript{a}, Yinghua Jin\textsuperscript{a}, Yongge Wu\textsuperscript{a}, Junqiu Liu\textsuperscript{b}, Wei Kong\textsuperscript{a,b,*}, Jiacong Shen\textsuperscript{b}

\textsuperscript{a}College of Life Science, Jilin University, Changchun 130012, PR China
\textsuperscript{b}Key Laboratory for Supramolecular Structure & Materials of Ministry of Education, Jilin University, Changchun 130012, PR China
\textsuperscript{c}Sichuan Tumor Hospital & Institute, Chengdu 610041, PR China

Received 9 March 2007; accepted 2 July 2007

Abstract

DNA vaccination has tremendous potential for treating or preventing numerous diseases for which traditional vaccines are ineffective but the technique can be limited by low immunogenicity. Current synthetic DNA delivery systems are versatile and safe, but substantially less efficient than viruses. Here, a novel multicomponent supramolecular system involving the preparation of mannose-bearing chitosan oligomers microspheres with entrapping complexes of DNA vaccine and polyethylenimine was developed to mimic many of the beneficial properties of the viruses. After delivery by intramuscular immunization in BALB/c mice, the microspheres induced an enhanced serum antibody responses two orders of magnitude greater than naked DNA vaccine. Additionally, in contrast to naked DNA, the microspheres induced potent cytotoxic T lymphocyte responses at a low dose. Consequently, formulation of DNA vaccines into multicomponent vectors is a powerful means of increasing vaccine potency.

\textcopyright{} 2007 Elsevier Ltd. All rights reserved.

Keywords: Mannose-bearing Chitosan oligomers microspheres; Supramolecular assembly; DNA vaccine; Artificial virus; Immunogenicity

1. Introduction

Immunization with DNA vaccines results in humoral and cellular immune responses that protect against disease in preclinical models of infectious diseases, cancer, and autoimmunity [1]. Intramuscular (i.m.) injection has been the primary route of administration for DNA vaccines, and has been shown to elicit protective and therapeutic immune responses in many animal models. However, optimal antibody and cytotoxic T lymphocyte (CTL) responses were induced with high doses of DNA in nonhuman primates and human volunteers [2–4]. Although it is difficult to quantitate the amount of plasmid DNA that enters cells or is degraded before they enter the nucleus and initiate gene expression, it is believed that \( \geq 90\% \) of the DNA injected never gets into the cytoplasm and of the \( \approx 10\% \) that does enter the cell, \( \leq 1\% \) enters the nucleus where gene expression occurs [5,6]. This lower bioavailability may be due to major cellular barriers such as plasma, endo/lysosomal and nuclear membranes, nuclease degradation \textit{in vivo}, and the fact that DNA has an overall net negative electrostatic charge [7,8]. Although the use of DNA vaccines at high doses is feasible, it would impose serious limitations on the number of constructs that could be included in a vaccine. In addition, the use of very high doses of DNA is less favorable from a process economics standpoint [9]. There is, therefore, a clear need to induce...
effective immunity in humans with lower and fewer doses of DNA, as well as to increase the magnitude of the immune response obtained.

There are a number of strategies available that have the potential to improve the potency of DNA vaccines. Several groups have attempted to improve the delivery using cationic microparticles [9], chitosan [10], non-ionic block co-polymers [11] and cationic liposomes [12,13]. Although such approaches have had some success, they are far from ideal because gene delivery is too complicated to be achieved with a single carrier molecule [14]. The viruses, having evolved in parallel with their hosts, have been employed in over 85% of gene therapy clinical trials because of their incredible gene delivery efficiency; however, few have proven to be immunogenic. A more promising direction would be to develop safer delivery vectors that would mimic key properties of viruses, a multi-component polymer, with each component performing a viral function [15,16].

Here we have designed novel mannose-bearing chitosan oligomers (MBCO) microspheres with entrapping polyethyleneimine (PEI)/DNA complexes to mimic the beneficial properties of viruses:

(i) **DNA condensation.** For viruses, the nucleic acids are protected by a protein coat or capsid, which can form a hollow, symmetrical structure enclosing coiled genetic materials. The core of the microsphere is a polycation (PEI) capable of inducing DNA condensation. Conversion of a filiform molecule into a compact particle improves both chemical stability and physical properties.

(ii) **Cell entry—targeting.** To enter their hosts, viruses divert the function of cell–matrix and cell–cell anchoring proteins, such as heparin sulfate proteoglycans (HSPGs) and integrins, which are responsible for cell entry by receptor-mediated endocytosis. Condensed DNA particles also require a specific surface for cell entry. For DNA vaccine, the activation of T-cell responses requires presentation of antigen by professional antigen presenting cells (APCs), and it has been shown by a number of groups that the presentation indeed occurs by professional bone marrow-derived APCs rather than by transfected muscle cells themselves [17,18]. In our approach, the surface of the microspheres is responsible for binding and entry to APCs. We decided to conjugate mannose to the surface of the microspheres because APCs, such as dendritic cells (DCs), express high levels of mannose receptor and mannose-related receptor, which are used for endocytosis and phagocytosis of a variety of antigens having exposed mannose and fucose residues.

(iii) **Endosome escape.** After internalization, DNA microspheres must escape from the formed intracellular vacuoles. Viruses that do not fuse at the plasma membrane exploit endosome acidification as an escape signal, by means of sophisticated conformational changes of fusion proteins. In MBCO microspheres, PEI shares the ability to buffer the acidity of endosomes. The vacuolar pH should therefore decrease more slowly, with a large concomitant ionic concentration increase. Osmotic swelling due to water entry may then burst the parvacuole and release the complexes into the cytoplasm. This is the famous ‘proton sponge’ hypothesis. After preparation and characterization, the microspheres were administered to experimental animals and the immune responses induced were compared with immunization with naked DNA. A significant improvement in immunogenicity over naked DNA was achieved for both CTL and antibody induction of the MBCO microspheres. This technology offers an improved way of delivering DNA vaccine to the nucleus of cell, by mimicking viruses in their ability to do the same.

2. Materials and methods

2.1. Materials

The 25kDa PEI (branched), NaBH(CN)₂, NaN₂, Mannobiose, Chitosan (MW 102kDa; 85% deacetylated) were purchased from Sigma-Aldrich. All reagents used were of the highest purity available. The HBV S/V1012 plasmid (CMV promoter, 5.7 kb), pLuc/V1012 plasmid (CMV promoter, 6.4 kb) and pEGFP/V1012 plasmid (CMV promoter, 5.8 kb) were constructed by our Lab and obtained by transforming Escherichia coli strain top10 and cultured under defined growth conditions. The plasmids were purified by using a Qiagen Plasmid Giga kit, and the final product was endotoxin free (<2.5 units/mg). Permission to do animal work was obtained from the Laboratory Animal Ethics Committee of Jilin University, China.

2.2. Synthesis of mannose-bearing chitosan oligomers

Mannose-bearing chitosan (M-chitosan) was obtained by reductive amination with mannobiose, as described in detail elsewhere [19]. The purified mannose-bearing chitosan was chemically treated with sodium nitrite in 1% acetic acid at 25°C for 30 min to produce chitosan oligomers of lower molecular weights, according to a method described by Peniston [20]. The oligomers were purified, lyophilized and used without further modification. The degree of substitution of mannosyl units on the chitosan was obtained from elementary analysis and distortionless enhancement of polarization transfer (DEPT) (135°) 13C NMR. Water solubility of mannose-bearing chitosan oligomer was estimated using the transmittance of the chitosan derivatives solution [21].

2.3. Preparation and characterization of MBCO microsphere

MBCO microspheres were prepared following the report of Aral and Akbuga [22] with slight modification. Briefly, PEI/DNA complexes (preparation and characterization in supporting information) were added to 50mM sodium sulfonate solution, and this mixture was quickly dropped into the mannose-bearing chitosan oligomers solution and vortexed for 15–30s. Formed microspheres were washed with deionized water and separated by centrifugation at 11000g, then freeze-dried. The size distribution of the MBCO microspheres was determined by dynamic light scattering (DLS) with a Zetasizer 3000 HS (Malvern Instruments, UK) and the value was calculated by volume measurement. The loading level of
the DNA in the microspheres was determined by assaying the supernatant after centrifugation and measuring DNA by absorbance at 260 nm. The encapsulation efficiency of microspheres was calculated. The Zeta potential of the microspheres was measured on the same apparatus as DLS. Selected batches of microspheres were evaluated by transmission electron microscopy (TEM) and atomic force microscopy (AFM) for size and shape. AFM images of the microspheres were taken with a Nanoscope IIIa AFM Multimode (Digital Instruments, Santa Barbara, CA) under ambient conditions. AFM was operated in the tapping mode with an optical readout using Si$_3$N$_4$ cantilevers (Nanoprobes, Digital Instruments). By replacing mannose-bearing chitosan oligomers with chitosan or M-chitosan, Chitosan and M-chitosan microspheres with encapsulated PEI/DNA can be prepared in the same method as MBCO microspheres.

2.4. In vitro and in vivo release

In vitro release studies of DNA from MBCO microspheres were carried out by suspending 10 mg of microspheres in 1 ml of FBS at pH 7.4 (120 mM NaCl, 2.7 mM KCl, 10 mM PBS, 10% FCS) at 37 °C under stirring. At predetermined time intervals, the suspension was centrifuged and replaced with the same volume of fresh medium. The DNA concentration in the supernatant was determined by UV absorbance at 260 nm. Each experiment was performed in triplicate. Release profiles of chitosan and M-chitosan microspheres with encapsulated PEI/DNA were performed as a control according to the same operation.

Initial burst release of DNA vaccine from microspheres is desirable for vaccination [9]. In vitro burst release studies of DNA from MBCO microspheres were carried out in COS-7 cells (sinim virus 40-transformed kidney cells of an African green monkey) using the GFP as reporter gene. Cells were grown at 37 °C in humidified air containing 5% CO$_2$ and passed every 2–3 days. The cells (1 × 10$^5$ per well) were plated on 24-well tissue-culture plates 24 h before use. Immediately before the initiation of the experiments, the medium was removed from each well, and the cells were washed once with DMEM without serum and antibiotics and treated with a dilution of MBCO, M-chitosan and chitosan microspheres. GFP expression was directly viewed under a fluorescence microscope (OLYMPUS America).

In vivo release of DNA from MBCO microspheres was carried in BALB/c mice, which were bred and cared in the animal facilities of the vaccine center of Jilin University, Changchun. Three groups of female BALB/c mice (n = 6) were injected with either 50 µg of pCMVLuc DNA, M-chitosan microspheres containing 50 µg of pCMVLuc DNA or the MBCO microspheres containing 50 µg of pCMVLuc DNA. Three groups of mice were injected i.m. in the anterior tibialis (TA) muscle on one leg. The muscle from each mouse was harvested either at day 1, 7, or day 14 after vaccination [9].

2.5. Gene expression in vitro

RAW264.7 cells (murine monocyte-macrophage cells) were cultured in DMEM medium containing Gln supplemented with 10% heated-inactivated FCS (from Gibco) and antibiotics (100 units/ml penicillin and 100 µg/ml streptomycin from Sigma). The cells (1 × 10$^5$ per well) were plated on 24-well tissue-culture plates 24 h before transfection. Immediately before the initiation of transfection experiments, the medium was removed from each well, and the cells were washed once with DMEM without serum and antibiotics and treated with a serial dilution of MBCO, M-chitosan and chitosan microspheres. A competition assay was carried out to confirm the uptake of MBCO microspheres mediated by mannose-receptor by adding 20 mM of mannose to MBCO microspheres suspension. Transfection with lipofectamine™ 2000-DNA complexes was performed as a positive control according to the manufacturer’s protocol. Luciferase gene expression was monitored 48 h later by using a commercial kit (Promega). Each transfection experiment was performed in triplicate and is expressed as mean light units per mg of cell protein ± SD.

2.6. Measurement of antibody responses and T-cell responses

Female BALB/c mice in groups of 8 were immunized with either the MBCO microspheres, naked DNA or control PBS at different doses. The immunization protocol was performed at weeks 0, 2, 4 and 6. Sera samples were collected from all mice by tail bleeding at different times points and HBsAg specific serum IgG titers were confirmed by enzyme-linked immunosorbent assay (ELISA).

Spleens from immunized mice were harvested 2 weeks after the fourth immunization and used in pools of five. Spleen cells were cultured with RPMI 1640 phenol red-free medium. Approximately 1 × 10$^6$ P815/BALB target cells were sensitized with synthetic epitope peptide at a concentration of 1 µm for 2 h at 37 °C. Cytotoxicity was measured by a standard lactate dehydrogenase (LDH)-release assay with a CTL kit (Promega) according to the instructions provided by the manufacture. The HBsAg-specific T cells in the spleen were also indirectly determined using cytokine enzyme-linked immunosorbent spot (ELISPOT) by measuring HBsAg induced IFN-γ production, which was performed according to the instruction of the murine IFN-γ ELISPOT kit (BD, USA).

2.7. Statistical analysis

Means and SD were obtained, Student’s T-test was conducted to analyze differences, and a p-value less than 0.05 was considered statistically significant.

3. Results

3.1. MBCO microspheres evaluation

We produced a low-molecular-weight chitosan by random depolymerization of M-chitosan, with an average molecular weight of 12 kDa (Table 1). In this study, PEI/DNA complexes were encapsulated into the chitosan, M-chitosan and MBCO microspheres (Table 2). DLS measurements of MBCO microspheres showed a unimodal particle size distribution between 200 and 300 nm. The zeta potential of MBCO microspheres was approximately 4.12 mV at pH 5.5 and close to neutral at pH 7.2. The low surface potential of MBCO microspheres is suitable for use in vivo due to the low reaction with components of the in vivo milieu. The MBCO microspheres obtained under these conditions appeared fairly spherical and polydisperse nature, as revealed by TEM and AFM image (Fig. 1).

3.2. In vitro and in vivo release study

The in vitro release of DNA from the MBCO microspheres showed initial burst release. In the first day, about 27.1% of the PEI/DNA complexes were released from MBCO microspheres, and no obvious release was detected for chitosan and M-chitosan microspheres at the first day. The molecular weight of chitosan and chitosan derivatives significantly affected the drug release (Fig. 2a). The in vitro burst release ability of MBCO microspheres was also evaluated in COS-7 cells using the pEGFP plasmid. In the experiment we observed that a higher
Table 1
The characteristics of chitosan, mannose-bearing chitosan (M-chito) and depolymerized mannose-bearing chitosan (DM-chito)

| Formulation | \( M_w \) (kDa) | Formula\(^a\) | pH\(^b\) |
|-------------|-----------------|---------------|---------|
| Chitosan    | 102             | \([\text{C}_{8}\text{H}_{13}\text{NO}_{5}]_{0.15}\text{C}_{6}\text{H}_{13}\text{NO}_{4}]_{0.85}\text{C}_{1}\text{H}_{2}\text{O}\) | 7.0 ± 0.5 |
| M-chito     |                 | \([\text{C}_{8}\text{H}_{13}\text{NO}_{5}]_{0.05}\text{C}_{6}\text{H}_{11}\text{NO}_{4}]_{0.65}\text{C}_{18}\text{H}_{33}\text{NO}_{14}]_{0.3}\text{C}_{1}\text{H}_{2}\text{O}\) | 9.0 ± 0.5 |
| DM-chito    | 12              |               | ≥ 12.0  |

\(^a\)Obtained from elementary analysis.

\(^b\)The highest pH that can dissolve the polymer; the pH of the polymer solution in 0.1N HCl was adjusted by adding stepwise 6N NaOH. The polymer was considered as an insoluble one when the transmittance of the polymer solution was lower than 50%, compared to that of a control solution (0.1N HCl). All data were expressed as mean ± SD (n = 3).

Table 2
Chitosan, M-chitosan and MBCO microspheres encapsulated PEI/DNA within it

| Formulation  | Mean size (nm)\(^a\) | Encapsulation efficiency (%) | Zeta potential (mV)\(^b\) |
|--------------|----------------------|-----------------------------|---------------------------|
| Chitosan     | 415.2 ± 44.2         | (94 ± 5.4)                  | 19.44 ± 2.78              |
| M-chitosan   | 326.3 ± 31.9         | (89 ± 2.6)                  | 10.19 ± 3.23              |
| MBCO         | 246.9 ± 30.8         | (82.5 ± 3.4)                | 4.12 ± 0.64               |
| PEI/DNA (N/P = 6) | 86.6 ± 30.2 | | 36.64 ± 1.77 |

\(^a\)The mean size of microspheres was measured by DLS.

\(^b\)The zeta potentials of chitosan derivatives microspheres was measured at pH 5.5 and PEI/DNA complexes were measured at pH 7.2. All data were expressed as mean ± SD (n = 3).

Fig. 1. Appearance and size of MBCO microspheres. (a) Transmission electron micrograph of MBCO microspheres. Scale bar represents 100 nm. (b) Atomic force micrograph of MBCO microspheres. Scale bar represents 500 nm. (c) Size distribution of freshly prepared microspheres. Size was measured using photon correlation spectroscopy (dynamic light scattering) and data were plotted as volume distribution.
percentage of transfected cells producing higher amounts of transgene product for MBCO (Fig. 2d) microspheres than for chitosan (Fig. 2b) and M-chitosan (Fig. 2c) microspheres. The faster release rate seems entirely appropriate, given evidence that most DCs die within 7 days after activation and migration to draining lymph nodes [23].

The in vivo release of DNA from MBCO microspheres was detected by the expression of luciferase after injection into TA muscle in BALB/c mice. The level of in vivo expression of luciferase was higher for MBCO microspheres than for naked DNA, chitosan and M-chitosan microspheres at the day of 1, 7 and 14 time point (Fig. 2e). The uptake and expression of naked plasmid in muscle cells...
may be related to muscle physiology and function, most likely via a receptor-mediated event involving the T tubules and caveolae. For naked DNA, peak level of gene expression in muscle was found between 7 and 14 days. And for chitosan, M-chitosan and MBCO microspheres, peak level of gene expression was found over 14 days post-injection, possibly explained by the controlled release of DNA. The MBCO microspheres based on chitosan oligomers dissociated more easily than the high-molecular-weight chitosan microspheres. The more easily dissociated microspheres mediated a faster onset of action and gave a higher gene expression after i.m. administration in vivo.

3.3. Transfection efficiency of MBCO microspheres in vitro

The in vitro transfection efficiency of MBCO microspheres was evaluated in RAW264.7 cells using the pCMV luciferase plasmid. RAW264.7 cells are well-known model cells of monocyte-macrophage cells, having rich mannose receptors on the cell surface. The results of the model cells of monocyte-macrophage cells, having rich mannose receptors on the cell surface. The results of the luminescence assay to detect the luciferase activity in the transfected cells indicated relatively high transfection efficiencies (Fig. 3). The expressed luciferase activity of MBCO was about three orders of magnitude higher than the background level (DNA transfection), and it was only about five to ten times lower than that of the Lipofectamine™2000. The expressed activity of chitosan and M-chitosan microspheres was about ten-fold lower than MBCO microspheres, and showed only a slight transfection efficiency. Furthermore, the decreased transfection activity by the addition of superfluous mannose demonstrated that MBCO microspheres might be internalized by endocytosis or phagocytosis via recognition of the mannose receptor on the surface of macrophages (Fig. 3).

3.4. Enhanced humoral and cellular immune responses with MBCO Microspheres

Though mouse bone marrow-derived DCs showed relatively lower mannose receptor levels than human DC, the mouse was a convenient model for DNA-based immunization. The formulated MBCO microspheres enhanced antibody responses to HBsAg protein over naked DNA at all time points (Fig. 4a). In an extensive dose–response titration assessed by ELISA, naked DNA primed HBsAg-specific antibody response after four continuous doses of DNA as high as 10 µg. In contrast, MBCO microspheres were effective at 100 ng, indicating a ~100-fold increase in DNA vaccine potency (based on the lowest dose of DNA required to prime a measurable response). In addition, MBCO microspheres accelerated the antibody responses. A detectable antibody responses to HBsAg were achieved within 5 weeks of injection of naked DNA at 10 µg doses, whereas only 3 weeks were required for MBCO microspheres at the same dose. This acceleration by 2 weeks is statistically significant, and is of clinical interest whenever a rapid immune response is critical.

HBsAg-specific CD8+ T cells were measured in vitro by assessing the death of P815 /BALB target cells which had been sensitized with HBsAg CTL epitope peptide. Naked DNA primed mild HBsAg-specific CD8+ T cells only at the highest DNA dose of 100 µg, whereas MBCO microspheres were effective at a dose as low as 1 µg, indicating a ~100-fold increase in DNA vaccine potency, as judged by reduction of DNA vaccine dose (Fig. 4b).

During natural infection, HBV-specific Th1 cells, CTL, and the associated antiviral cytokines (IFN-γ, TNF-α, IL-2) may play key roles in virus resolution [24–26]. HBsAg-specific CD8+ T cells were measured in vitro by determining IFN-γ production in spleen cells in response to brief restimulation with CTL epitope, as measured by ELISPOT (Fig. 4c). MBCO microspheres immunization at 10 µg clearly corresponded to naked DNA at 100 µg doses, which indicated a ~100-fold increase in DNA vaccine potency, as judged by reduction of DNA vaccine dose.

4. Discussion

Viruses, having evolved in parallel with their human hosts, are a superior gene delivery system. There has been interest in designing “Artificial viruses” which mimic aspects of this delivery system [27, 28]. A virus contains a single genetic (DNA or RNA) molecule which is coiled with a specific number of capsid proteins in a compact viral size (20–250 nm). Monomolecularity, stoichiometry, and size in addition to transfection ability are the golden criteria for artificial viruses. There is little doubt that viral characteristics can be incorporated into nonviral vectors to enhance delivery efficiency, but it is not necessary that delivery systems of the future must be “viruslike” particles. Instead, by understanding and incorporating the extremely efficient mechanisms of infection by viruses, DNA delivery systems will be viruslike in function, not necessarily in shape—just as our aviation systems mimic the function of birds, but not always their morphology [29]. Based on previous studies, the ideal “artificial virus” system should possess the following properties: ease of assembly; efficient
delivery leading to total transfection; stabilization of DNA before and after uptake; capability of traversing the presumed barriers to gene delivery (e.g., by incorporating viral components or mimicking viral characteristics); efficient decomplexation or “unpackaging” (e.g., intracellular controlled release) and efficient nuclear targeting. While no current nonviral systems have all these properties, biopolymers provide versatile chemistry with a wide variety of different functionalities. In addition, they are relatively cheap to produce. So, biopolymers are excellent candidates for construction of artificial viruses.

In this study, we have designed novel MBCO microspheres to specifically address these desirable characteristics.

(i) The mannose-bearing chitosan oligomers were chosen as an inert coat to enclose the DNA vaccine. Chitosan has been proposed as non-toxic biodegradable polycationic polymers with an extensive record of safe use for gene delivery systems [30, 31]. In most of these studies, commercially available chitosans of high-molecular weight (100–400 kDa) were used. Unfortunately, these chitosans biodegrade slowly, which delays the release of the DNA. Another pharmaceutical drawback is their low solubility at physiological pH and their viscosity-enhancing properties at concentrations suitable for in vivo gene therapy [32]. We therefore produced a low-molecular weight version with an average molecular weight of 12 kDa chitosan by random depolymerization of chitosan (Table 1). The more easily dissociated chitosan oligomers gave a 10-fold higher gene expression in RAW264.7 cells in vitro as compared to the more stable high-molecular weight chitosan (Fig. 3). In addition, MBCO microspheres induced a higher luciferase expression in vivo than stable high-molecular weight chitosan microspheres at day of 1, 7 and 14 time points. Both our in vitro and in vivo data suggest that dissociation of the chitosan oligomer microspheres is a fast process for the release of DNA from the microspheres and the subsequent onset of action, compared to a biodegradation-dependent release [33]. Additionally, covalent attachment of mannose to the primary amine function of chitosan can target APCs and be internalized via recognition of the mannose receptor on the surface of APCs such as Mφs (Fig. 3). The mechanism of the adjuvant effect achieved with MBCO microspheres is not currently known, but we believe that efficient delivery to APCs may be an important contributing factor.

(ii) The core of the MBCO microspheres is a polycation (PEI) capable of inducing DNA condensation. PEI has been used for gene and oligonucleotide transfer into cells in culture and in vivo. It can, however, be rapid inactivation due to undesired interactions with components of the in vivo milieu. Polycations are generally less immunogenic than viruses: however, their activation of innate defense mechanisms is a major problem. Complement system activation by PEI has been demonstrated, with highly positive complexes being the most active stimulators [34]. In current study, activation of the complement cascade might be avoided by shielding the positive particles with mannose-bearing chitosan oligomers (Table 2). In addition, PEI possesses the ability to buffer the acidity of endosomes and is able to escape from them, based on
the ‘proton sponge’ hypothesis. The former chitosan-based systems were the inefficient release from endosomes into the cytoplasm, causing low transfection efficiency [35]. In our system, a synergistic effect on transfection efficiency was clearly observed by the combined use of chitosan and PEI (data not shown). Hence, the MBCO microspheres mimic the following five desirable characteristics of a virus: (i) DNA condensation; (ii) cell entry—targeting; (iii) endosome escape; (iv) compact viral size (200–300 nm) and (v) efficient decomplexation.

Biopolymer-based artificial viruses have the potential to become highly efficient, versatile, and safe DNA vaccine vectors. In doing so, they may replace recombinant viruses as the standard vehicle for genetic vaccine. However, we must first engineer the polymers to improve the delivery of genes from outside the target cell to the nucleus. Genetic vaccine vectors of future will be constructed much like viruses, multifunctional supramolecular systems that self-assemble around DNA, each component performing a function imitative of viral characteristics.

5. Conclusion

These studies have demonstrated that MBCO microspheres were potent delivery systems for DNA vaccines and are capable of inducing the enhanced humoral and cellular responses (about 100-fold) after i.m. immunization with HBsAg plasmid. Another key advantage of this system is its speed of immune induction. In recent years, outbreaks of Ebola virus, severe acute respiratory syndrome, and influenza A have caused concern that conventional DNA vaccination strategies are too slow at inducing immunity [36,37]. This study has served to highlight the exciting potential of multifunctional supramolecular systems as a method of induction of a rapid immune response to DNA vaccines. In subsequent studies, several new biomaterials have been designed which overcome specific important gene delivery barriers. Further enhancements are needed to reach the gene delivery efficiency obtained by viruses, but results are encouraging and ultimately this technology holds great promise for use in humans.

Acknowledgments

We thank Prof. Xiao-Fang Yu (Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, John Hopkins University) for advice and technical assistance. We thank Valerie Clack (Duke University) for editorial assistance. We also thank Dr. Qi-Feng Wang at Jilin University for his help with AFM measurements. This work was supported by a Grant from NSFC (20674029 and 30371317) to Wei Kong.

References

[1] Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccine. Ann Rev Immunol 1997;15:617–48.
[2] Letvin NL, Montefiori DC, Yasutomi Y, Perry HC, Davies ME, Lekatis C, et al. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci USA 1997;94:9178–83.
[3] Calatota S, Bratt G, Nordland S, Hinkula J, Leandersson AC, Sandstrom E, et al. Cellular cytotoxic responses induced by DNA vaccination in HIV-1-infected patients. Lancet 1998;351:1320–5.
[4] Wang R, Doolan DL, Le TP, Hedstrom RC, Coonan KM, Charoenvit Y, et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998;282:476–80.
[5] Boutorine AS, Kostina EV. Reversible covalent attachment of cholesterol to oligodeoxy-ribonucleotides for studies of the mechanisms of their penetration into eukaryotic cells. Biochimie 1993;75:35–41.
[6] Barry ME, Pinto-Gonzalez D, Orson FM, McKenzie GJ, Petry GR, Barry MA. Role of endogenous endonucleases and tissue site in transfection and CpG-mediated immune activation after naked DNA injection. Hum Gene Ther 1999;10:2461–80.
[7] Hasan UA, Abai AM, Harper DR, Wren BW, Morrow WJ. Nucleic acid immunization: concepts and techniques associated with third generation vaccines. J Immunol Methods 1999;229:1–22.
[8] Pouton CW, Seymour LW. Key issues in non-viral gene delivery. Adv Drug Deliv Rev 2001;46:187–203.
[9] Singh M, Briones M, Ott G, O’Hagan D. Cationic microparticles: a potent delivery system for DNA vaccines. Proc Natl Acad Sci USA 2000;97:811–6.
[10] Illum L, Jabbal-Gill I, Hinchcliffe M, Ficher AN, Davis SS. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 2001;51:81–96.
[11] Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002;415:331–5.
[12] Felgner JH, Kumar R, Sridhar CN, Wheeler CJ, Tsai YJ, Border R, et al. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J Biol Chem 1994;269:2550–61.
[13] Gregoriadis G, McCormack B, Obrenovic M, Safdie R, Zadi B, Perrie Y. Vaccine entrapment in liposomes. Methods 1999;19:156–62.
[14] Somia N, Verma IM. Gene therapy: trial and tribulations. Nat Rev Genet 2000;1:91–9.
[15] Ogris M, Wagner E. Targeting tumors with non-viral gene delivery systems. Drug Discov Today 2002;7:479–85.
[16] Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang RK, et al. Tumor regression by targeted gene delivery to the neovasculature. Science 2002;296:2404–7.
[17] Cott M, Lee DJ, Carson DA, Tighe H. Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med 2001;193:1565–75.
[18] Doe B, Selby M, Barnett S, Baenziger J, Walker CM. Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells. Proc Natl Acad Sci USA 1996;93:8578–83.
[19] Mansur Y, Laurance DH. Some chemical and analytical aspects of polysaccharide modifications. 3. Formation of branch-chain, soluble chitosan derivatives. Macromolecules 1984;17:272–81.
[20] Peniston OP. 1975; USP, 3922260.
[21] Park JH, Cho YW, Chung H, Kwon IC, Jeong SY. Synthesis and characterization of sugar-bearing chitosan derivatives: aequous solubility and biodegradability. Biomacromolecules 2003;4:1087–91.
[22] Aral C, Akbuga J. Preparation and in vitro transfection efficiency of chitosan microspheres containing plasmid DNA: poly(L-lysine) complexes. J Pharm Pharm Sci 2003;6:321–6.

[23] Garg S, Oran A, Wajchman J, Sasaki S, Maris CH, Kapp JA, et al. Genetic tagging shows increased frequency and longevity of antigen-presenting, skin-derived dendritic cells in vivo. Nat Immunol 2003;4:907–12.

[24] Deml L. Purification and characterization of hepatitis B virus surface antigen particles produced in Drosophila Schneider-2 cells. J Virol Methods 1999;79:205–17.

[25] Rico MA, Quiroga JA, Subira D, Castanon S, Esteban JM, Pardo M, et al. Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha. Hepatology 2000;33:295–300.

[26] Seder RA, Hill AV. Vaccines against intracellular infections requiring cellular immunity. Nature 2000;406:793–8.

[27] Nakai T, Kanamori T, Sando S, Aoyama T. Remarkably size-regulated cell invasion by artificial viruses. Saccharide-dependent self-aggregation of glycoviruses and its consequences in glycoviral gene delivery. J Am Chem Soc 2003;125:8465–75.

[28] Zuber G, Zammut-Italiano L, Dautey E, Behr JP. Targeted gene delivery to cancer cells: directed assembly of nanometric DNA particles coated with folic acid. Angew Chem Int Ed Engl 2003;42:2666–9.

[29] Luo D, Saltzman WM. Synthetic DNA delivery systems. Nat Biotechnol 2000;18:33–7.

[30] Lee MK, Chun SK, Kim JK, Choi SH, Kim A, Ounqgho K, et al. The use of chitosan as a condensing agent to enhance emulsion-mediated gene transfer. Biomaterials 2005;26:2147–56.

[31] Onishi H, Machida Y. Biodegradation and distribution of watersoluble chitosan in mice. Biomaterials 1999;20:175–8.

[32] Koping-Hoggard M, Tubulekas I, Guan H, Edwards K, Nilsson M, Varum KM, et al. Chitosan as a nonviral gene delivery system. Structure-property relationships and characteristics compared with polyethylenimine in vitro and after lung administration in vivo. Gene Ther 2001;8:1108–21.

[33] Lavertu M, Methot S, Tran-Khanh N, Buschmann MD. High efficiency gene transfer using chitosan/DNA nanoparticles with specific combinations of molecular weight and degree of deacetylation. Biomaterials 2006;27:4815–24.

[34] Plank C, Mechtler K, Szoka Jr FC, Wagner E. Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. Hum Gene Ther 1996;7:1437–46.

[35] Kim TH, Kim SI, Akaike T, Cho CS. Synergistic effect of poly(ethyleneimine) on the transfection efficiency of galactosylated chitosan/DNA complexes. J Control Release 2005;105:354–66.

[36] Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000;408:605–9.

[37] Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, Roederer M, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003;424:681–4.